Employees and unionists hold a picket line as part of a strike against the sale of Sanofi's subsidiary Opella, in support of employees, for industrial jobs and economic sovereignty, called by the CGT and FO workers' unions outside the Sanofi manufacturing plant in Lisieux, northwestern France, on October 17, 2024. The planned sale of France's best-selling medical drug Doliprane, manufactured by Opella, a subsidiary of French multinational pharmaceutical and healthcare company Sanofi, to US investors has caused the government a splitting headache after an outcry from politicians on all sides. (Photo by LOU BENOIST / AFP) (Photo by LOU BENOIST/AFP via Getty Images)

A unionist takes part in a picket line as part of an employees' strike against the sale of Sanofi's subsidiary Opella, in support of employees, for industrial jobs and economic sovereignty, called by the CGT and FO workers' unions outside the Sanofi manufacturing plant in Lisieux, northwestern France, on October 17, 2024. The planned sale of France's best-selling medical drug Doliprane, manufactured by Opella, a subsidiary of French multinational pharmaceutical and healthcare company Sanofi, to US investors has caused the government a splitting headache after an outcry from politicians on all sides. (Photo by LOU BENOIST / AFP) (Photo by LOU BENOIST/AFP via Getty Images)

Employees and unionists hold a picket line as part of a strike against the sale of Sanofi's subsidiary Opella, in support of employees, for industrial jobs and economic sovereignty, called by the CGT and FO workers' unions outside the Sanofi manufacturing plant in Lisieux, northwestern France, on October 17, 2024. The planned sale of France's best-selling medical drug Doliprane, manufactured by Opella, a subsidiary of French multinational pharmaceutical and healthcare company Sanofi, to US investors has caused the government a splitting headache after an outcry from politicians on all sides. (Photo by LOU BENOIST / AFP) (Photo by LOU BENOIST/AFP via Getty Images)

Employees and unionists hold a picket line as part of a strike against the sale of Sanofi's subsidiary Opella, in support of employees, for industrial jobs and economic sovereignty, called by the CGT and FO workers' unions outside the Sanofi manufacturing plant in Lisieux, northwestern France, on October 17, 2024. The planned sale of France's best-selling medical drug Doliprane, manufactured by Opella, a subsidiary of French multinational pharmaceutical and healthcare company Sanofi, to US investors has caused the government a splitting headache after an outcry from politicians on all sides. (Photo by LOU BENOIST / AFP) (Photo by LOU BENOIST/AFP via Getty Images)

A placard reading "No arms (no workforce), no Doliprane" is pictured as employees and unionists hold a picket line as part of a strike against the sale of Sanofi's subsidiary Opella, in support of employees, for industrial jobs and economic sovereignty, called by the CGT and FO workers' unions outside the Sanofi manufacturing plant in Lisieux, northwestern France, on October 17, 2024. The planned sale of France's best-selling medical drug Doliprane, manufactured by Opella, a subsidiary of French multinational pharmaceutical and healthcare company Sanofi, to US investors has caused the government a splitting headache after an outcry from politicians on all sides. (Photo by LOU BENOIST / AFP) (Photo by LOU BENOIST/AFP via Getty Images)

A unionist takes part in a picket line as part of an employees' strike against the sale of Sanofi's subsidiary Opella, in support of employees, for industrial jobs and economic sovereignty, called by the CGT and FO workers' unions outside the Sanofi manufacturing plant in Lisieux, northwestern France, on October 17, 2024. The planned sale of France's best-selling medical drug Doliprane, manufactured by Opella, a subsidiary of French multinational pharmaceutical and healthcare company Sanofi, to US investors has caused the government a splitting headache after an outcry from politicians on all sides. (Photo by LOU BENOIST / AFP) (Photo by LOU BENOIST/AFP via Getty Images)

Employees and unionists hold a picket line as part of a strike against the sale of Sanofi's subsidiary Opella, in support of employees, for industrial jobs and economic sovereignty, called by the CGT and FO workers' unions outside the Sanofi manufacturing plant in Lisieux, northwestern France, on October 17, 2024. The planned sale of France's best-selling medical drug Doliprane, manufactured by Opella, a subsidiary of French multinational pharmaceutical and healthcare company Sanofi, to US investors has caused the government a splitting headache after an outcry from politicians on all sides. (Photo by LOU BENOIST / AFP) (Photo by LOU BENOIST/AFP via Getty Images)

Employees and unionists hold a picket line as part of a strike against the sale of Sanofi's subsidiary Opella, in support of employees, for industrial jobs and economic sovereignty, called by the CGT and FO workers' unions outside the Sanofi manufacturing plant in Lisieux, northwestern France, on October 17, 2024. The planned sale of France's best-selling medical drug Doliprane, manufactured by Opella, a subsidiary of French multinational pharmaceutical and healthcare company Sanofi, to US investors has caused the government a splitting headache after an outcry from politicians on all sides. (Photo by LOU BENOIST / AFP) (Photo by LOU BENOIST/AFP via Getty Images)